Skip to content

Clinical evaluation of the efficacy and safety of an injectable gel containing stabilized(cross linked) hyaluronic acid under the brand name Luwefill Haylo

Clinical evaluation of the efficacy and safety of an injectable gel containing stabilized(cross linked) hyaluronic acid under the brand name Luxefill Haylo for facial skin rejuvenation and improvement of elasticity and hydration

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150101020514N38
Enrollment
20
Registered
2026-01-17
Start date
2026-02-02
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin aging. Changes in skin texture

Interventions

Intervention group: 2 sessions of injection with the injectable product Luxefill Haylo(an injectable gel containing stabilized hyaluronic acid (from Atra zist aray Company) subcutaneously using the 5-

Sponsors

Atra zist aray company
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 35 and 60 years old Present visible signs of skin ageing symptoms mainly skin dryness skin roughness, loss of elasticity and appearance of fine lines Possibility to accompany the visit plans and study process Signing an informed consent form and agreed to follow up.

Exclusion criteria

Exclusion criteria: Previous treatment with hyaluronic acid fillers in the facial area within the past year Experience with RF, rejuvenation lasers or intense pulsed light in the past 6 months Systemic diseases affecting skin health such as collagen vascular diseases, diabetes, hypothyroidism, as well as liver and renal failure. History of systemic use of skin-related medicine such as glucocorticoids, isotretinoin, immunomodulators and hormonal medicine in the past 3 months Currently pregnant or lactating Smoking in the past two years

Design outcomes

Primary

MeasureTime frame
Skin elasticity. Timepoint: Before intervention, 4 and 12 weeks after the second injection(8 and 16 week). Method of measurement: Cutometery by MPA 580.

Secondary

MeasureTime frame
Stratum corneum hydration. Timepoint: Before intervention, 4and 12 weeks after the second injection (8 and 16 week). Method of measurement: Corneometry by MPA 580.;Skin condition for signs of skin aging including clear lines and wrinkles. Timepoint: Before intervention, 4and 12 weeks after the second injection (8 and 16 week). Method of measurement: Using GAIS scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026